The most recent issue of the CDC’s Morbidity and Mortality Weekly Report (MMWR) includes the 2012-2013 information on seasonal influenza vaccination, including recommendations for who should be vaccinated and strains covered by this year’s vaccines.
According to the agency:
U.S. influenza vaccines for 2012–13 will contain A/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage) antigens. The influenza A(H3N2) and B antigens differ from the respective 2010–11 and 2011–12 seasonal vaccine antigens. The influenza A(H1N1) vaccine virus strain is derived from an influenza A(H1N1)pdm09 (2009[H1N1]) virus and was included in the 2009(H1N1) monovalent pandemic vaccine as well as the 2010–11 and 2011–12 seasonal vaccines.
The CDC is recommending routine annual vaccination for “for all persons aged ≥6 months,” with certain limitations on who may safely receive the live intranasal version.
Additional details are provided on patients with egg allergies, dose considerations for children ages 6 months through 8 years, available vaccine products, and febrile seizures associated with administration of influenza and 13-valent pneumococcal conjugate (PCV-13) vaccines.
2012-2013 Vaccine Information Sheets for both inactivated and live intranasal influenza vaccines are provided at http://www.cdc.gov/vaccines/pubs/vis/#flu. Translations in multiple languages are also available for both the inactivated and live intranasal vaccines.